Log In
BCIQ
Print this Print this
 

VY-FXN01

  Manage Alerts
Collapse Summary General Information
Company Voyager Therapeutics Inc.
DescriptionAdeno-associated virus (AAV) -based gene therapy delivering the frataxin (FXN; FRDA) gene
Molecular Target Frataxin (FXN) (FRDA)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationAtaxia
Indication DetailsTreat Friedreich's ataxia (FRDA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$845.0M

$70.0M

$745.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/11/2015

$845.0M

$70.0M

$745.0M

Get a free BioCentury trial today